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Francisella tularensis is the causative agent of the acute disease tularemia. Due to its
extreme infectivity and ability to cause disease upon inhalation, F. tularensis has been
classified as a biothreat agent. Two subspecies of F. tularensis, tularensis and holarctica,
are responsible for tularemia in humans. In comparison, the closely related species
F. novicida very rarely causes human illness and cases that do occur are associated
with patients who are immune compromised or have other underlying health problems.
Virulence between F. tularensis and F. novicida also differs in laboratory animals. Despite
this varying capacity to cause disease, the two species share ∼97% nucleotide identity,
with F. novicida commonly used as a laboratory surrogate for F. tularensis. As the
F. novicida U112 strain is exempt from U.S. select agent regulations, research studies
can be carried out in non-registered laboratories lacking specialized containment facilities
required for work with virulent F. tularensis strains. This review is designed to highlight
phenotypic (clinical, ecological, virulence, and pathogenic) and genomic differences
between F. tularensis and F. novicida that warrant maintaining F. novicida and F. tularensis
as separate species. Standardized nomenclature for F. novicida is critical for accurate
interpretation of experimental results, limiting clinical confusion between F. novicida and
F. tularensis and ensuring treatment efficacy studies utilize virulent F. tularensis strains.
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INTRODUCTION AND OVERVIEW
F. tularensis was first isolated in 1912 as the causative agent
of a plague-like disease affecting squirrels in Tulare county,
California (McCoy and Chapin, 1912). Subsequently, Edward
Francis, for whom the genus is named, established that sev-
eral clinical syndromes in humans were caused by F. tularen-
sis and proposed the name “tularemia” to describe the illness
(Francis, 1925). In 1950 researchers isolated a bacterium from salt
water collected from Ogden Bay, Great Salt Lake, Utah (Larson
et al., 1955). Initial experiments revealed the bacterium resem-
bled F. tularensis morphologically, but fermented sucrose, was
of lesser virulence than F. tularensis and did not cross-react
with serum from rabbits inoculated with heat, ether, formalin,
or phenol killed F. tularensis (Larson et al., 1955). Based on
these phenotypic differences, the isolate was given the unique
species name F. novicida (Larson et al., 1955). The classifica-
tion of F. novicida as a distinct species was further substantiated
in 1964 as a result of its less fastidious growth requirements
as compared to F. tularensis and the lack of heterologous vac-
cine protection in mice immunized with killed F. novicida and
challenged with several F. tularensis strains (Owen et al., 1964).
Additionally, guinea pigs injected subcutaneously with rabbit
immune serum against either F. tularensis or F. novicida followed
by challenge with antigen preparations from both F. tularen-
sis and F. novicida showed antibody adsorption to homolo-
gous but not heterologous antigen at the sight of serum injec-
tions (i.e., passive cutaneous anaphylaxis assay) (Owen et al.,
1964).
DNA-DNA hybridization experiments performed with
F. tularensis and F. novicida in the 1980s indicated a high degree
of genetic relatedness between the two (≥92% at 50◦C; ≥86% at
65◦C) (Hollis et al., 1989). On this basis, it was proposed, though
not validly published that F. novicida be reassigned as a subspecies
of F. tularensis (F. tularensis subsp. novicida) (Hollis et al., 1989;
Lapage, 1992; Tindall et al., 2006). To meet Bacteriological Code
requirements, a proposal to transfer F. novicida to the subspecies
rank of F. tularensis (i.e., F. tularensis subsp. novicida) was validly
published in 2010 in the International Journal of Systematic and
Evolutionary Microbiology (IJSEM) (Tindall et al., 2006; Huber
et al., 2010). This proposal was met with formal objection in
IJSEM, as it was based solely on genetic relatedness and did not
take into consideration the documented phenotypic and genomic
differences between F. tularensis and F. novicida (Johansson et al.,
2010). Indeed, in the 2010 publication proposing reclassification
of F. novicida, 11 metabolic traits unique to F. novicida as
compared to F. tularensis were identified but not considered
with respect to its suggested reassignment as F. tularensis subsp.
novicida (Huber et al., 2010).
In recent decades, an explosion in the amount of basic
research focused on understanding and treating tularemia
has occurred due to concern about the intentional misuse
of F. tularensis as a bioweapon (Dennis et al., 2001; Cowley
and Elkins, 2011). Research studies using virulent F. tularen-
sis strains can be particularly challenging, as they can only
be handled under BSL-3 conditions and, in the U.S., within
laboratories that are Tier 1 select agent approved (Federal
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Register, 2012). In contrast, the F. novicida type strain U112
is exempt from select agent regulations in the U.S. and can
be handled under standard BSL-2 laboratory conditions
(Federal Register, 2012). Information about select agent exemp-
tions for F. tularensis can be found at the following website
www.selectagents.gov/Select%20Agents%20and%20Toxins%20
Exclusions.html#francisella. The less stringent containment
requirement for F. novicida U112, its high genetic identity to
F. tularensis, its ability to infect macrophages in vitro, to cause
illness in laboratory mice, and ease of genetic manipulation as
compared to F. tularensis have all contributed to widespread use
of F. novicida U112 as a surrogate for F. tularensis (Anthony et al.,
1991; Mdluli et al., 1994; Schmerk et al., 2009; Cowley and Elkins,
2011).
To date, the appropriate nomenclature for F. novicida remains
controversial and non-standardized. While F. novicida is recog-
nized on the Approved List of Bacterial Names (Skerman et al.,
1980), F. tularensis subsp. novicida is validly published (Huber
et al., 2010), resulting in two different names and no clear
decision on the correct nomenclature. As a result, a variety of
names including, but not limited to, F. tularensis, F. tularensis
subsp. novicida, Ft novicida, Ftn, Ftt, Fn, and F. novicida, have
all been used in the published literature. This lack of standard-
ized terminology is further complicated by non-enforcement of
consistent nomenclature by journals and editors. It is particularly
problematic when trying to interpret published experimental
results obtained using F. novicida U112, but described only as
F. tularensis with no strain information included. Another neg-
ative outcome of the proposed classification of F. novicida as a
subspecies of F. tularensis is that other F. novicida strains, exclud-
ing the exempt U112 strain, are considered select agents in the
US, despite the fact they do not cause tularemia. In order to sup-
port maintaining separate species designations for F. novicida and
F. tularensis, genomic as well as clinical, virulence, ecologic and
pathogenic differences between the two organisms are reviewed
here (Table 1). We also discuss the utility of F. novicida as a lab-
oratory surrogate for F. tularensis with respect to treatment of
tularemia.
HUMAN DISEASE AND TRANSMISSION
F. tularensis is one of the most infectious bacterial pathogens
known. Studies in human volunteers in the 1960s demonstrated
that infection was established with as few as 25 organisms
when aerogenically exposed to F. tularensis subsp. tularensis,
with clinically overt disease occurring 3–5 days post exposure
(McCrumb, 1961). Two subspecies of F. tularensis, tularen-
sis (also called type A) and holarctica (also called type B),
cause human tularemia (Petersen and Molins, 2010). Between
these two subspecies, disease outcome and geographic dis-
tribution differs (Olsufiev et al., 1959). F. tularensis subsp.
tularensis causes disease only in North America and is asso-
ciated with higher mortality in humans as compared to
F. tularensis subsp. holarctica, which causes less severe illness
throughout the Northern Hemisphere (Olsufiev et al., 1959).
Human infection due to a third subspecies, F. tularensis subsp.
mediasiatica, has never been documented in the published
literature.
Within both F. tularensis subsp. tularensis and subsp. holarc-
tica, distinct subpopulations have been delineated by a number of
different genotyping methods (Petersen andMolins, 2010). In the
case of F. tularensis subsp. tularensis, pulsed field gel electrophore-
sis defined three subpopulations, A1a, A1b, and A2, which differ
with respect to clinical outcome (Kugeler et al., 2009). Among
patients infected with A1b strains, significantly higher fatality
rates were observed as compared to those patients infected with
A1a or A2 strains (Kugeler et al., 2009). The higher mortality
rate for infection with an A1b strain was not associated with
host factors (age, sex, underlying illness), indicating an intrinsic
characteristic of A1b strains (i.e., virulence) is responsible for the
observed difference (Kugeler et al., 2009).
F. tularensis causes the zoonotic, vector-borne disease
tularemia. Clinical expression of tularemia in humans depends
primarily on the route of transmission (Tärnvik and Berglund,
2003; WHO, 2007). Humans acquire infections by a variety
of different mechanisms, including arthropod bites (ticks, flies,
mosquitoes), direct contact with infected animals (e.g., skinning
animals after hunting), ingestion of water or food contaminated
by infected animals, and inhalation of infective aerosols (Dennis
et al., 2001; WHO, 2007). For all forms, fever and acute symp-
toms are hallmarks of tularemia in healthy individuals. Arthropod
transmission of F. tularensis causes glandular and ulceroglandular
forms of tularemia, with the latter form of disease presenting as an
ulcer at the site of the arthropod bite. Skinning infected animals
also leads to ulceroglandular tularemia. Other forms of tularemia
include oculoglandular tularemia, acquired via direct inoculation
of the eye; oropharyngeal tularemia, acquired through inges-
tion of water or food contaminated by infected animals; and
pneumonic (respiratory) tularemia, acquired through inhalation
of infective aerosols during landscaping, farming, or laboratory
activities. It is the pneumonic form of tularemia that is the most
severe and of highest concern with respect to an intentional
aerosol event (Dennis et al., 2001).
In comparison to F. tularensis, F. novicida infection is not asso-
ciated with healthy individuals. F. novicida infection in humans is
exceedingly rare and therefore often difficult to diagnose accu-
rately (Brett et al., 2012; Birdsell et al., 2009). Only 12 cases
have been documented (Hollis et al., 1989; Clarridge et al., 1996;
Leelaporn et al., 2008; Birdsell et al., 2009; Brett et al., 2012;
Respicio-Kingry et al., 2012; Sjödin et al., 2012; Whitehouse et al.,
2012). An F. novicida-like infection was reported in an Australian
patient, however, genome comparisons indicate the strain is more
similar to F. hispanensis (Whipp et al., 2003; Sjödin et al., 2012).
Illness caused by F. novicida does not resemble tularemia. Clinical
information available for 11 reported cases indicate that 9 of
the F. novicida cases occurred in patients who were immuno-
compromised or had underlying health problems (Hollis et al.,
1989; Clarridge et al., 1996; Leelaporn et al., 2008; Birdsell et al.,
2009; Brett et al., 2012; Respicio-Kingry et al., 2012; Whitehouse
et al., 2012). Fever and acute disease, hallmarks of tularemia in
healthy individuals, were only observed for F. novicida infections
in compromised patients (Hollis et al., 1989; Clarridge et al.,
1996; Leelaporn et al., 2008; Brett et al., 2012; Respicio-Kingry
et al., 2012; Whitehouse et al., 2012). In the two healthy indi-
viduals with F. novicida infection, regional lymphadenopathy,
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Table 1 | Genetic and phenotypic differences between F. tularensis and F. novicida.
F. tularensisa F. novicidab References
Genome Size 1,892,819 bp 1,910,031 bp Larsson et al., 2005; Rohmer et al., 2007
Protein coding genes 1445 1731 Larsson et al., 2005; Rohmer et al., 2007
Pseudogenes 254 14 Rohmer et al., 2007
FPI 2 copies 1 copy Nano et al., 2004; Larsson et al., 2005
Restriction modification
systems
1 gene 4 functional
systems/6 genes
Gallagher et al., 2008
CRISPR/Cas No Yes Sampson et al., 2013; Schunder et al., 2013
O-antigen 15 genes 12 genes; aa identity
to Ft 98% to 20%
Thomas et al., 2007; Sjödin et al., 2012
Recombination No Yes Larsson et al., 2009
IS element proliferation Yes No Larsson et al., 2009
Clinical Tularemia Yes No Francis, 1925
Transmission Vector-borne, animal
contact, inhalation of
aerosols
Salt water; brackish
water
Larson et al., 1955; Dennis et al., 2001; Brett
et al., 2012; Whitehouse et al., 2012
Ecology Animal hosts Zoonotic: small
mammals,
lagomorphs
No Hopla, 1974; Jellison, 1974
Arthropod hosts Ticks, flies,
mosquitoes
No Jellison, 1974; Petersen et al., 2009b
Virulence
(LD50 by
subcutaneous or
intradermal
route of
infection)
Mice 1 CFU Range from 10 to
>107 CFU
Bell et al., 1955; Larson et al., 1955; Olsufiev
et al., 1959; Owen et al., 1964;
Meshcheriakova et al., 1995; Kieffer et al.,
2003
Guinea pig 1 CFU Range from 10 to
>105 CFU
Bell et al., 1955; Olsufiev et al., 1959;
Meshcheriakova et al., 1995
Rabbit 1 CFU >108 CFU Olsufiev et al., 1959; Meshcheriakova et al.,
1995
(LD50 by
intranasal or
intratracheal
route of
infection)
Mice <10 CFU Approximate LD50 of
10 CFU
Lauriano et al., 2004; Pechous et al., 2008
Fischer 344 rats 5 × 102CFU Approximate LD50 of
5 × 106 CFU
Ray et al., 2010
Mechanisms of
pathogenicity
Cytokine induction upon
cellular uptake
No Yes Butchar et al., 2008; Dai et al., 2013
Inflammasome activation Delayed Yes Mariathasan et al., 2006; Weiss et al., 2007b;
Fernandes-Alnemri et al., 2010; Dotson et al.,
2013
CRISPR/cas mediated TLR2
evasion
No Yes Dai et al., 2013; Sampson and Weiss, 2013a,b
PI3K/Akt signaling No; miR-155
suppressed
Yes; miR-155
induced
Cremer et al., 2009
Pulmonary cell association Alveolar
M/dendritic cells
Alveolar
M/neutrophils
Hall et al., 2008
O-antigen role Intracellular
replication
Complement
resistance
Thomas et al., 2007; Case et al., 2014
Knockout of iclR or galE
genes attenuates virulence in
mice
No Yes Mortensen et al., 2010; Thomas et al., 2011
aSpecific numbers given are in reference to F. tularensis subsp. tularensis Schu S4, except for virulence which is from (Olsufiev et al., 1959) strain Schu.
bSpecific numbers given are in reference to F. novicida U112.
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lacking fever or other symptoms, was reported (Hollis et al.,
1989; Birdsell et al., 2009). Classic forms of tularemia, including
ulceroglandular, pneumonic, oropharyngeal, and oculoglandular,
have not been observed for F. novicida infection in healthy
individuals.
Given the rarity of F. novicida infection in humans, little is
knownwith regards to how the organism is transmitted. Reported
human infections are associated with uncertain routes of expo-
sure. For those cases where the mode of infection was ascertained,
two cases were due to near-drowning events in salt water and
three cases were associated with environmental contamination of
outdoor ice machines (Brett et al., 2012; Respicio-Kingry et al.,
2012; Whitehouse et al., 2012). No evidence exists to suggest that
F. novicida is transmitted by animals or arthropod vectors (see
Ecology section).
ECOLOGY
In nature, F. tularensis and F. novicida occupy distinct ecological
niches; F. tularensis is a classic vector-borne zoonotic pathogen,
whereas F. novicida is not. As an intracellular pathogen, F. tularen-
sis (both subsp. tularensis and subsp. holarctica) infects and causes
disease and mortality in a large number of animal hosts (Hopla,
1974; Jellison, 1974). The bacterium is most often associated
with lagomorphs and rodents, including voles, squirrels, and
beavers. F. tularensis is also found in nature in a number of
arthropod vectors, including ticks, flies, and mosquitoes, which
bite both animal and human hosts and thereby transmit the
organism (Petersen et al., 2009b). Maintenance of F. tularensis in
nature involves a cycle in which mammals serve as the amplify-
ing hosts and arthropod vectors feed on these bacteremic hosts
to disseminate the bacterium to other animals (Petersen et al.,
2009b).
In contrast to F. tularensis, the identification of F. novicida
has never been reported in wild animals (healthy or mori-
bund), indicating that in nature F. novicida is not a zoonotic
bacterium. F. novicida has also never been identified in arthro-
pod vectors in nature. Moreover, in the case of arthropods,
the lack of identification of F. novicida does not appear to be
due to inadequate testing methods as numerous Francisella-
like endosymbionts have been identified in ticks via PCR and
sequencing (Scoles, 2004; Goethert and Telford, 2005; Kugeler
et al., 2005; Machado-Ferreira et al., 2009; De Carvalho et al.,
2011; Ivanov et al., 2011; Kreizinger et al., 2013). As arthro-
pod vectors characteristically acquire infection from bacteremic
animal hosts, the lack of identification of F. novicida in arthro-
pods is consistent with the presumed inability F. novicida to
cause bacteremia in wild animals. It is likely that F. novicida
resides in an environmental niche and is propagated in nature
via a mechanism that does not involve mammalian or arthropod
hosts. Indeed, the sole source of F. novicida isolates to date has
been salt water. This includes the F. novicida U112 type strain as
well as 9 other F. novicida isolates (Larson et al., 1955; Petersen
et al., 2009a; Whitehouse et al., 2012). Additional environmen-
tal sources of F. novicida, including brackish water and soil, have
been implicated based on PCR detection and sequencing anal-
ysis (Barns et al., 2005; Kuske et al., 2006; Berrada and Telford,
2010).
GENOMICS
Genome sequencing has been performed on several F. tularen-
sis and F. novicida strains, with a limited number of genomes
fully assembled and annotated (Larsson et al., 2005; Beckstrom-
Sternberg et al., 2007; Chaudhuri et al., 2007; Rohmer et al.,
2007; Barabote et al., 2009; Champion et al., 2009; Larsson et al.,
2009; Modise et al., 2012; Sjödin et al., 2012; Svensson et al.,
2012; Antwerpen et al., 2013). Consistent with the high degree
of genetic similarity previously determined via DNA-DNA re-
association (Hollis et al., 1989), the average nucleotide identity
observed across 1.1 MB of genomic sequence from 3 F. novicida
strains and 13 F. tularensis strains (8 subsp. holarctica, 1 subsp.
mediasiatica, 2 subsp. tularensis A1, and 2 subsp. tularensis A2)
is ≥97.7% (Larsson et al., 2009). Despite this high degree of
nucleotide identity, differences are apparent between their respec-
tive genomes. F. novicida U112 has a larger genome of 1,910,031
bases with more protein coding genes (1731) as compared to
F. tularensis. The genome size of F. tularensis subsp holarctica
LVS and F. tularensis subsp. tularensis Schu S4 is 1,895,998 and
1,892,819 bases, with 1380 and 1145 protein coding genes, respec-
tively (Rohmer et al., 2007; Larsson et al., 2009).
Selective genome reduction in the intracellular pathogen
F. tularensis is clear; the F. tularensis subsp. tularensis Schu S4
and F. tularensis subsp. holarctica LVS genomes contain 254 and
303 pseudogenes, respectively (Rohmer et al., 2007). In contrast,
only 14 pseudogenes are evident in the F. novicida U112 genome
(Rohmer et al., 2007). Larsson et al. identified a total of 279 gene
losses present in six F. tularensis genomes (3 subsp. holarctica, 1
subsp. mediasiatica, and 2 subsp. tularensis strains) as compared
to the F. novicida U112 genome (Larsson et al., 2009). Frequently
it is components of metabolic pathways that are deleted during
the transition to an intracellular pathogen, as the nutrients can
be acquired from the host. Indeed, metabolic differences between
F. novicida and F. tularensis date back to early characterization
of F. novicida, when it was found to be less fastidious compared
to F. tularensis (Owen et al., 1964). More recently, Huber et al.
identified 11 different metabolic traits present only in F. novi-
cida as compared to F. tularensis subsp. tularensis, F. tularensis
subsp. holarctica, and F. tularensis subsp. mediasiatica (Huber
et al., 2010). Genomic analyses of F. novicida U112, F. tularen-
sis subsp. tularensis Schu S4, and F. tularensis subsp. holarctica
LVS indicate 41.2 percent of the genes predicted to be involved
in amino acid biosynthesis in F. novicida U112 are inactivated in
one or both F. tularensis strains (Rohmer et al., 2007). F. novicida
U112 appears to have 3 incomplete amino acid synthesis path-
ways (lysine, histidine, and methionine) whereas in F. tularensis
subsp. tularensis Schu S4 there are 9 incomplete pathways (argi-
nine, histidine, lysine, tyrosine, methionine, cysteine, threonine,
valine, and isoleucine) (Larsson et al., 2005; Rohmer et al., 2007;
Meibom and Charbit, 2010; KEGG, 2014).
The F. novicida U112 genome encodes 84 genes (including
those involved in amino acid biosynthesis) that are inactivated
in both F. tularensis subsp. tularensis Schu S4 and F. tularensis
subsp. holarctica LVS (Rohmer et al., 2007). The predicted
function of these genes (carbohydrate metabolism, amino acid
biosynthesis, metabolite transport, energymetabolism, transport,
and DNA restriction/modification) is consistent with F. novicida
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maintaining the ability to exist in the environment, outside
animal hosts. For example, F. novicida U112 encodes 4 intact
restriction barrier systems in its genome that impair acquisition
of foreign methylated DNA by as much as 106 fold over native
F. novicida U112 DNA, suggesting F. novicida resides in a niche
where it encounters foreign DNA (Maier et al., 2004; Gallagher
et al., 2008). The majority of genes encoding restriction bar-
rier systems in F. tularensis genomes (subsp. tularensis Schu S4
and WY96-3418, subsp. holarctica LVS, FTA, and OSU18, and
subsp. mediasiatica) are present in the form of pseudogenes,
suggesting that with its transition to an intracellular pathogen,
restriction barrier systems were no longer necessary for survival
(Gallagher et al., 2008). This evolutionary phenomenon is also
present in strains of increasing virulence in both Yersinia and
Burkholderia (Ong et al., 2004; Kim et al., 2005; Gallagher et al.,
2008). Another example of F. novicida retaining functions for
environmental survival and persistence is the identification of 5
genes (FTN_0451-0456) encoded in the F. novicidaU112 genome
that are responsible for the synthesis and breakdown of the sec-
ondary messenger, bis—(3′–5′)—cyclic dimeric GMP (cdGMP)
(Zogaj et al., 2012). Overproduction of cdGMP in F. novicida
U112 initiates biofilm formation as well as attenuates its ability
replicate within mouse macrophages. The absence of these genes
in F. tularensis suggests their elimination provided a selective
advantage to its pathogenic intracellular life-cycle (Zogaj et al.,
2012).
Gene amplification is evidenced in F. tularensis genomes as
compared to F. novicida genomes. Most notably, genomic anal-
yses of F. tularensis (6 subsp. tularensis, 12 subsp. holarctica, and
2 subsp. mediasiatica strains) and F. novicida (9 strains) indicate
a duplication of the 30 kbp Francisella Pathogenicity Island (FPI)
in F. tularensis as compared to F. novicida which contains only a
single copy (Nano et al., 2004; Larsson et al., 2005, 2009; Rohmer
et al., 2007). The FPI consists of 16–19 genes comprising a Type VI
secretion system (T6SS) (Nano et al., 2004; Nano and Schmerk,
2007; De Bruin et al., 2011). Deletion of most genes within the
FPI of both F. tularensis and F. novicida generates mutants that
are defective for intra-macrophage growth and severely attenu-
ated for virulence in mice (Tempel et al., 2006; Maier et al., 2007;
Nano and Schmerk, 2007; Bröms et al., 2010; De Bruin et al.,
2011; Chou et al., 2013). Given the importance of the FPI for
intracellular replication and virulence, it seems likely duplication
in F. tularensis represents a unique adaptation to its intracellular
niche.
Only 7 genes unique to F. tularensis were identified via com-
parative genomic analysis of 20 F. tularensis strains (6 subsp.
tularensis, 12 subsp. holarctica, and 2 subsp. mediasiatica); coun-
terparts to these genes are absent in 9 F. novicida strains (Sjödin
et al., 2012). All 7 genes are predicted to encode components
necessary for the outer surface of F. tularensis cells (Sjödin
et al., 2012). FTT0794, FTT0795, and FTT0796 are part of
12.5 kb locus important for formation of a capsule-like com-
plex on the surface of F. tularensis (Bandara et al., 2011; Zarrella
et al., 2011). The proteins encoded by these genes contain con-
served domains for methyltransferase (FTT0795) and phospho-
choline metabolism (FTT0794 and FTT0796) (Thomas et al.,
2011). FTT1453c (wzx), FTT1454c (wbtJ), and FTT1458 (wzy)
encode proteins involved in lipopolysaccharide O-antigen synthe-
sis (Sjödin et al., 2012). The wbtJ gene of F. tularensis encodes
an N-formyltransferase which converts the O-antigen sugar,
dTDP-4,6-dideoxy-4-amino-D-glucose to dTDP-4,6-dideoxy-4-
formamido-D—glucose, while the wzy gene product is an O-
antigen polymerase whose function is to catalyze addition of
newly synthesized O-antigen repeat units (Kim et al., 2010;
Zimmer et al., 2013). FTT1188 encodes a hypothetical membrane
protein lacking significant homology to known proteins (Sjödin
et al., 2012).
Genomic analyses indicate that F. tularensis and F. novi-
cida evolved as two distinct populations (Larsson et al., 2009).
F. tularensis strains are highly clonal, differentiating them from
F. novicida strains, which are characterized by a propensity for
recombination. Recombination was noted in 10% of the 742
Francisella core genes tested in seven F. novicida genomes, whereas
there was no evidence of recombination in these same genes
when 20 F. tularensis genomes were examined (Larsson et al.,
2009; Sjödin et al., 2012). Additionally, the F. tularensis Schu S4
genome shows evidence of 79 IS element insertions compared to
only 26 IS element insertions in the F. novicida U112 genome
(Rohmer et al., 2007). Genome decay due to IS element prolif-
eration is clear in F. tularensis; IS elements in F. tularensis are
responsible for at least 22 percent of inactivated genes (Larsson
et al., 2009). IS element proliferation in F. tularensis is also pro-
posed to be responsible for duplication of the FPI in F. tularensis
(Rohmer et al., 2007; Larsson et al., 2009). Between F. novi-
cida and F. tularensis, substantial differences are also observed in
the ratio of substitution rates at non-synonymous and synony-
mous sites (dN/dS), with high dN/dS ratios for all F. tularensis
branches, and considerably lower ratios for F. novicida (Larsson
et al., 2009). Overall, these findings are consistent with the idea
that niche restricted bacteria, such as intracellular pathogens, tend
to have monomorphic genomes, whereas environmental bacte-
ria are under weaker purifying selection and therefore retain
the capacity to adapt to differing conditions by undergoing
genomic changes (Moran, 2002; Achtman, 2008; Larsson et al.,
2009).
VIRULENCE
The differing virulence between F. tularensis subspecies was classi-
cally determined by measuring the number of organisms required
to kill 50–100% of infected mice, guinea pigs, and rabbits (Francis
and Felton, 1953; Bell et al., 1955; Olsufiev et al., 1959). Variation
in the time-to-death of F. tularensis-infected animals was also
linked to virulence differences between F. tularensis subspecies
(Olsufiev et al., 1959). Summarized in this section are results of
virulence testing for F. novicida and F. tularensis by two routes
of infection (subcutaneous and pulmonary) in mice, guinea pigs,
rabbits, and rats. We note that the intent of this section is not to
discuss the merits of using one animal model over another for
tularemia research.
Both mice and guinea pigs are highly susceptible to F. tularen-
sis (both subsp. tularensis and subsp. holarctica) when introduced
via routes that mimic infection due to arthropod bite, with an
observed LD100 of only 1 organism for subcutaneous inoculation
(Bell et al., 1955; Olsufiev et al., 1959). The differing virulence
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between F. tularensis subsp. tularensis and F. tularensis subsp. hol-
arctica in guinea pigs and mice manifests as a shortened time
to death; F. tularensis subsp. tularensis infected mice and guinea
pigs (<1000 organisms) die markedly earlier as compared to
those infected with F. tularensis subsp. holarctica (Bell et al., 1955;
Olsufiev et al., 1959). Differences in time to death of infected
mice are also detected between subpopulations of F. tularensis
subsp. tularensis. Intradermal infection of C57BL/6 mice with 10–
20 CFUs results in significantly shortened survival times for those
mice infected with A1b strains as compared to those infected with
either A1a or A2 strains (Molins et al., 2010), consistent with
human epidemiologic data indicating A1b strains have higher vir-
ulence than other F. tularensis subsp. tularensis strains (Kugeler
et al., 2009).
In contrast to mice and guinea pigs, virulence is markedly
different in rabbits between F. tularensis subsp. tularensis and
F. tularensis subsp. holarctica. When introduced subcutaneously,
an LD100 of 1 organism is observed for F. tularensis subsp. tularen-
sis opposed to 109 organisms for F. tularensis subsp. holarctica
(Bell et al., 1955; Olsufiev et al., 1959). White rats are less sus-
ceptible to F. tularensis subsp. tularensis infection as compared to
rabbits; an LD100 of 108–109 was reported for subcutaneous infec-
tion by either F. tularensis subsp. tularensis or F. tularensis subsp.
holarctica (Olsufiev et al., 1959).
The virulence of F. novicida upon subcutaneous introduction
appears to be less than F. tularensis in mice, guinea pigs and rab-
bits, although the exact extent of the difference is difficult to
quantify. There is limited data in the literature with respect to
the number of F. novicida organisms required to kill animals as
determined by LD50 or LD100 studies. Similarly, there is a lack
of published data comparing time to death of animals infected
with F. tularensis vs. F. novicida. Initial experiments performed
with F. novicida U112 indicated 50 organisms introduced sub-
cutaneously was sufficient to kill 100% (4 of 4) of infected mice
and guinea pigs (Larson et al., 1955). Owen et al. subsequently
reported that 10–100 cells of F. novicida U112 were required to
kill a mouse and 10–1000 cells required to kill a guinea pig,
although no primary data or route of infection was provided
(Owen et al., 1964). Experiments using BALB/cByJ mice infected
intradermally with F. novicida U112 determined an LD50 of 2400
CFU (Kieffer et al., 2003). Much higher lethal doses for F. novicida
introduced subcutaneously were reported in a study published in
the Russian literature (Meshcheriakova et al., 1995). An LD50 of
1.3 × 104 organisms and LD100 of ∼107, >108, >108 organisms
was determined upon subcutaneous infection of outbred mice
with F. novicida U112, F. novicida F6168, and F. novicida D9876,
respectively (Meshcheriakova et al., 1995). In the same study,
an LD100 > 105 organisms was identified for all three F. novi-
cida strains (U112, F6168, D9876) via subcutaneous infection of
guinea pigs, and in rabbits no mortality was observed with 108
organisms of each strain (Meshcheriakova et al., 1995).
In recent years, the intranasal route of infection has been
used to induce respiratory illness in mice, given the severity of
pneumonic tularemia and the potential impact of an intentional
aerosol release of F. tularensis. Published studies are consistent
with a difference in virulence between F. tularensis subsp. tularen-
sis Schu S4 and F. novicida U112 via this route of infection.
An LD50 of <10 CFUs was determined for F. tularensis subsp.
tularensis Schu S4 in BALB/c mice (Pechous et al., 2008) and
100% mortality is reported for infection of C57BL/6, BALB/c,
and BALB/cByJ with 13-25 CFU (Qin et al., 2008; Cong et al.,
2009; Child et al., 2010; Okan et al., 2013; Richard et al., 2014).
For F. novicida U112, an approximate LD50 of 10 CFU was deter-
mined in inbred mice by intranasal inoculation, with two of five
BALB/c mice surviving an inoculum of 30 CFU, and one of five
surviving an inoculum of 300 CFU (Lauriano et al., 2004). In
C57BL/6 and BALB/c mice, 100% mortality is reported using
doses ranging from 100 to 445 CFU of F. novicida U112 (Pammit
et al., 2004; Mares et al., 2008; Sharma et al., 2009).
Significant virulence differences between F. tularensis and
F. novicida are evident upon pulmonary infection of Fischer 344
rats via intratracheal instillation (Ray et al., 2010). Fischer 344 rats
show the highest sensitivity to F. tularensis subsp. tularensis Schu
S4 (approximate LD50 of 5 × 102 CFU) as compared to F. tularen-
sis subsp. holarctica OR96-0246 (approximate LD50 of 1 × 105
CFU) (Ray et al., 2010). In contrast, Fischer 344 rats are highly
resistant to F. novicidaU112 infection, with an approximate LD50
of 5 × 106 CFU (Ray et al., 2010). Of note, a rapid time to death
(MTD = 3 days) was observed in the rats which succumbed to
infection with F. novicida, as compared to rats which died due to
infection with F. tularensis (MTD = 10 days), suggesting death
due to F. novicida was likely a toxic effect from the large number
of organisms rather than from a productive infection (Ray et al.,
2010).
MECHANISMS OF PATHOGENESIS
As described in this review, the genomes of F. novicida and
F. tularensis are highly similar, with the vast majority of genes in
F. tularensis also found in F. novicida. Despite this overall genetic
similarity, evidence indicates differential regulation of and dis-
tinct roles for homologous genes in F. tularensis and F. novicida
as pertains to pathogenesis. Moreover, F. tularensis has devel-
oped strategies distinct from F. novicida to evade host immune
responses. This section will focus on some of the differences that
have been described to date.
Evidence that the same genes in F. novicida and F. tularensis
play distinct roles in pathogenesis comes from knockout stud-
ies of homologous genes. For example, inactivation of the genes
encoding the transcriptional regulator IclR or the UDP-glucose-
4-epimerase GalE resulted in attenuation of F. novicidaU112, but
not F. tularensis subsp. tularensis Schu S4 in a mouse model of
infection (Weiss et al., 2007a; Mortensen et al., 2010; Thomas
et al., 2011). In the case of the dsbB gene, which encodes disulfide
bond formation B protein, deletion mutants were attenuated in
both F. tularensis subsp. tularensis Schu S4 and F. novicida U112.
However, F. novicida U112 knockouts provided protection from
challenge with F. novicidaU112, while F. tularensis subsp. tularen-
sis Schu S4 mutants provided no homologous protection (Tempel
et al., 2006; Qin et al., 2008). Intramacrophage secretion of FPI
proteins also differs between F. tularensis and F. novicida. Upon
infection ofmacrophages, 8 FPI proteins (IglE, IglC, IglI, IglJ, IglF,
VgrF, PdpE, and PdpA) were secreted by F. tularensis subsp. hol-
arctica LVS, whereas only 4 (IglE, IglC, PdpE, and PdpA) were
secreted by F. novicida, suggesting fundamental differences may
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exist between the two species with respect to the Type VI secretion
mechanism (Bröms et al., 2012).
The cell surface, a critical pathogenicity determinant, differs
between F. tularensis and F. novicida. Early studies indicated a
lack of serum cross-reactivity between F. tularensis and F. novi-
cida. More recently all genes unique to F. tularensis as compared
to F. novicida were predicted to encode outer surface compo-
nents (see Genomics section) (Larson et al., 1955; Owen et al.,
1964; Sjödin et al., 2012). Indeed, distinct structures for the core
oligosaccharide and O-antigen of F. tularensis and F. novicida
LPS have been described. The core oligosaccharide of F. tularen-
sis lacks a glucose residue attached to the β-glucose branch as
compared to F. novicida (Vinogradov et al., 2002; Vinogradov
and Perry, 2004; Gunn and Ernst, 2007; Okan and Kasper,
2013), while the O-antigen of F. tularensis contains two distinct
sugar moieties at either end of the tetra-saccharide repeat and
is present in longer oligomer chains as compared to F. novicida
(Vinogradov et al., 2004; Thomas et al., 2007; Barker et al., 2014).
Reflecting the observed structural variation, three of the genes
in the O-antigen encoding locus are unique to F. tularensis (see
Genomics section) and among the other 12 genes, amino acid
identity ranges from 98% to as low as 20% (Thomas et al., 2007;
Sjödin et al., 2012). The structurally and antigentically unique
O-antigens from F. tularensis and F. novicida appear to play dif-
ferent roles in the pathogenicity of each strain. In F. tularensis,
the O-antigen is critical for intracellular survival as an O-antigen
mutant (wbtDEF) (Thomas et al., 2007; Jones et al., 2012) is sig-
nificantly attenuated for intracellular growth as compared to a
similar wbtDEF mutant in F. novicida, which replicates normally
in macrophages (Thomas et al., 2007). Recent evidence indicates
that the O-antigen of F. tularensis subsp. tularensis Schu S4 pro-
tects it from autophagic detection once it reaches the cytosol
(Case et al., 2014).
The cell surface of F. tularensis also plays an important role
in cell entry and evasion of the host innate immune response.
Within host serum, the function of complement proteins is
to recognize pathogens and protect the host by direct lysis of
the pathogen or opsonization leading to phagocytosis. Both
F. tularensis and F. novicida have been shown to fix human
complement protein C3 on their surface, but are resistant to com-
plement mediated lysis due to rapid conversion of C3b to C3bi
(Clay et al., 2008). This conversion of C3 leads to the interaction
of C3bi with complement receptor protein C3R on host cells and
cellular uptake by phagocytosis (Clemens et al., 2005; Ben Nasr
and Klimpel, 2008; Clay et al., 2008; Dai et al., 2013). Deposition
of C3 on F. novicida has been shown to increase both the pro-
duction of reactive oxygen species (ROS) by human neutrophils
and the production of TNFα, IL-6, and IL-1β by human mono-
cytes (Barker et al., 2009; Dai et al., 2013). In stark contrast, C3
deposition on F. tularensis subsp. holarctica LVS resulted in sig-
nificantly less ROS production by human neutrophils, and C3
deposition on F. tularensis subsp. tularensis Schu S4 was directly
linked to suppression of the host immune response as monitored
by the decreased production of the proinflammatory cytokines,
TNFα, IL-6, and IL-1β, during uptake by human monocytes
(Barker et al., 2009; Dai et al., 2013). Taken together, these results
suggest different means of cellular entry for F. tularensis and
F. novicida and also differential effects on the early host immune
response.
A side-by-side comparison of pulmonary infection by
F. tularensis or F. novicida in C57BL/6 mice demonstrated dis-
similar cell types were infected in vivo. One day post-infection,
via the intranasal route, F. tularensis subsp. tularensis Schu S4,
F. tularensis subsp. holarctica LVS, and F. novicida U112 were
preferentially associated with alveolar macrophages, although this
proportion differed at 78.9, 70.3, and 51.6%, respectively (Hall
et al., 2008). Strikingly, 27.3% of F. novicida infected cells on day
1 were neutrophils as compared to only 0 and 0.4% for F. tularen-
sis subsp. tularensis Schu S4 and F. tularensis subsp. holarctica
LVS, respectively (1000 fold difference in the number of neu-
trophils), indicating that neutrophils responded to and phagocy-
tosed F. novicida U112 to a significantly greater extent than they
did F. tularensis (Hall et al., 2008). Moreover, increasing numbers
of alveolar macrophages and dendritic cells were infected from
day 1 to 3 following inhalation with either F. tularensis subsp.
tularensis Schu S4 or F. tularensis subsp. holarctica LVS, but not
for F. novicida U112, suggesting more rapid killing of F. novicida
infected cells (Hall et al., 2008).
Within host cells, F. tularensis and F. novicida display distinct
abilities to evade the host immune response. The formation of
the inflammasome, a multi-protein complex present in the host
cell cytoplasm, is activated by microbial components to induce
maturation of the inflammatory cytokines, interleukin IL-1β and
IL-18, thereby leading to death of infected cells (Bauernfeind
and Hornung, 2013). F. novicida is unable to efficiently evade
this host innate immune response, and is recognized by the
inflammasome upon escape from the phagosome and entry into
the host cell cytoplasm (Mariathasan et al., 2006; Weiss et al.,
2007b; Fernandes-Alnemri et al., 2010; Jones et al., 2012; Dotson
et al., 2013). In contrast, F. tularensis successfully escapes inflam-
masome activation early in infection (∼12 h) via a mechanism
involving suppression of TLR2 signaling (Dotson et al., 2013).
Presumably, this early suppression of the inflammasome allows
F. tularensis time to successfully replicate to high levels in the
cytoplasm prior to host cell death (Dotson et al., 2013).
Toll-like receptors (TLRs) play a central role in initiat-
ing innate cellular immune responses (Lim and Staudt, 2013).
Evasion of TLR2 signaling has been shown to be involved in
the intracellular replication of both F. tularensis and F. novi-
cida, although the mechanism utilized diverges between the
two bacteria (Telepnev et al., 2003; Katz et al., 2006; Malik
et al., 2006; Abplanalp et al., 2009; Dai et al., 2013). Within
the phagosome, F. novicida down-regulates the production of
an endogenous transcript (FTN_1103), encoding a TLR2 stim-
ulating lipoprotein, in a CRISPR/Cas system dependent manner
(Sampson et al., 2013; Sampson and Weiss, 2013a,b). In con-
trast, F. tularensis lacks both the functional CRISPR/Cas system
as well as the FTN_1103 homolog; genomic analyses indicate sig-
nificant disruption/degradation of these genes (Schunder et al.,
2013; Sampson and Weiss, 2013b). Rather, F. tularensis appears
to evade TLR2 activation via a mechanism that involves the
PI3K/Akt pathway, which when activated leads to production of
the pro-inflammatory cytokines IL-6, IL-8, and IL-1β (Butchar
et al., 2008; Cremer et al., 2009, 2011; Medina et al., 2010). The
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P13K/Act pathway is subject to negative regulation by the enzyme
SHIP and a cellular micro-RNA, miR-155 (Cremer et al., 2009,
2011). Induction of miR-155 down-regulates SHIP to promote
activation of the P13/Act pathway and inflammatory cytokine
production. F. tularensis subverts or suppresses the induction of
miR-155, thereby repressing the PI3K/Akt pathway. In contrast,
F. novicida strongly induces miR-155, leading to activation of
the P13K/Act pathway and the production of TNFα and IL-6 by
human monocytes (Cremer et al., 2009, 2011).
TREATMENT
Development of novel therapeutics for the treatment of tularemia
is an area of active research given concern regarding the poten-
tial misuse of F. tularensis as a bioweapon. Standard antimicrobial
therapy is effective for the treatment of tularemia, with amino-
glycosides, tetracyclines, and chloramphenicol approved for treat-
ment of tularemia by the U.S. Food and Drug Administration.
Although ciprofloxacin and other fluoroquinolones are not cur-
rently FDA-approved for treatment of tularemia, they show very
good efficacy against F. tularensis in vitro, in animals, and in
humans (Johansson et al., 2000, 2002; Steward et al., 2006;
Klimpel et al., 2008; Meric et al., 2008; Urich and Petersen, 2008;
Nelson et al., 2010; Weber et al., 2012).
Antibiotic resistance to frontline therapeutics recommended
for treatment of tularemia has never been identified in natu-
rally occurring strains of F. tularensis or F. novicida (Ikäheimo
et al., 2000; Garcia Del Blanco et al., 2004; Tomaso et al., 2005;
Urich and Petersen, 2008; Valade et al., 2008; Georgi et al., 2012).
Although treatment failure has been documented for human
cases of tularemia, it is not associated with spontaneous antibi-
otic resistance, but rather a delay in antibiotic initiation (Celebi
et al., 2006; Meric et al., 2008; Kaya et al., 2011). Nonetheless,
antibiotic resistance remains a concern, whether spontaneous or
intentionally engineered. In vitro experiments demonstrate that
both F. tularensis and F. novicida have the ability to rapidly acquire
resistance to quinolones. Passage of either F. tularensis subsp.
holarctica LVS or F. novicida U112 on increasing concentrations
of ciprofloxacin resulted in resistance to homologous classes of
drugs (Sutera et al., 2014). Of note, in the case of F. novicida,
but not F. tularensis subsp. holarctica, cross-resistance to het-
erologous classes of antimicrobials, including doxycycline and
erythromycin, was observed (Sutera et al., 2014). This suggests
F. novicida U112 encodes other genes not present in F. tularensis
that confer multidrug resistance and is consistent with genomic
comparisons indicating more transporters are present in the
genome of F. novicida U112 (Rohmer et al., 2007; Sutera et al.,
2014).
New therapeutic approaches for tularemia range from target-
ing the organism itself to modulating the host response in order
to mount a protective response. These therapeutic approaches
are covered in other chapters of this series. For approval and
licensure of new therapeutics for tularemia, direct evaluation
of the product’s efficacy in a clinical setting is needed. Because
therapeutic efficacy testing is not always feasible in a clinical set-
ting (e.g., limited numbers of cases), the U.S. Food and Drug
Administration developed the “Animal Rule” (21 CFR 314.610
and 21 CFR 601.91) to allow animal efficacy data to support
product licensure or approval. Of note with respect to F. tularensis
and F. novicida, the “Animal Rule” states that the etiological agent
used in animal studies generally should be identical to the one
that causes human disease. As discussed above, F. novicida does
not cause tularemia in humans and differences between F. novi-
cida and F. tularensis are also apparent in animals, indicating that
F. novicida should not substitute for F. tularensis in efficacy test-
ing of therapeutics. As recent studies indicate virulence differs
among F. tularensis subsp. tularensis strains in humans (Kugeler
et al., 2009; Molins et al., 2010), the use of more virulent A1b
strains should be considered for therapeutic efficacy testing in
animals.
CONCLUSIONS AND PERSPECTIVE
Bacterial species have traditionally been defined on the basis
of DNA-DNA hybridization values (Lapage, 1992; Stackebrandt
et al., 2002). The importance of phenotypic differences, however,
cannot be understated with respect to classification of bacterial
species. In 2002, the ad-hoc committee for the re-evaluation of
bacterial species definition stated: “Phenotype, including chemo-
taxonomic markers, will remain important diagnostic properties
in a species description. The ecological role can, in certain cases,
decide on the species status. For example, medical organisms
with defined clinical symptoms may continue to bear names that
may not necessarily agree with their genomic relatedness so as
to avoid unnecessary confusion among microbiologists and non-
microbiologists [‘nomen periculosum’ according to Rule 56a(5)
of the International Code of Nomenclature of Bacteria (Lapage,
1992)]” (Stackebrandt et al., 2002). A classic example of the value
in utilizing phenotypic data to maintain distinct species designa-
tions comes from the bacteria Yersinia pestis and Yersinia pseudo-
tuberculosis. Although these two bacteria share >97% nucleotide
identity across 75% of their genes, they retain individual species
names, due to their striking clinical and ecological differences
(Chain et al., 2004; Carniel et al., 2006). Y. pestis causes the highly
fatal vector-borne disease, plague, whereas Y. pseudotuberculosis is
transmitted by the fecal-oral route and infection rarely leads to
death.
In this review, we have highlighted clinical, ecological,
genomic, virulence, and pathogenic differences between F. novi-
cida and F. tularensis that when considered in conjunction with
genetic identity clearly warrants maintaining F. novicida and
F. tularensis as separate species (Table 1). F. tularensis causes the
zoonotic vector-borne disease tularemia, whereas F. novicida does
not. As determined by whole genome comparisons, F. tularen-
sis evolved independently of F. novicida, which is consistent with
its completely distinct ecological niche (F. tularensis is a zoonotic
pathogen whereas F. novicida is not) and mechanisms of trans-
mission (F. tularensis is transmitted by arthropod vectors whereas
F. novicida is not). Moreover, as part of F. tularensis’ pathogenic
intracellular lifestyle, it has developed strategies distinct from
F. novicida to evade host immune responses and successfully
propagate in animal hosts.
F. novicida and its mutants have clearly contributed to our
understanding of the biology of F. tularensis. A classic exam-
ple was the discovery of the 30 kbp FPI in F. novicida (Gray
et al., 2002; Nano et al., 2004). In more recent years, side-by-side
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experiments including both F. novicida and F. tularensis have
highlighted the value of direct comparison between the two
as pertains to understanding the unique pathogenic mecha-
nisms F. tularensis has evolved to elicit its extreme virulence
(Vinogradov et al., 2002, 2004; Vinogradov and Perry, 2004;
Thomas et al., 2007; Butchar et al., 2008; Hall et al., 2008;
Cremer et al., 2009; Mortensen et al., 2010; Bröms et al., 2012;
Dai et al., 2013; Dotson et al., 2013; Sutera et al., 2014). As we
move forward, findings utilizing the select agent exempt F. novi-
cida U112 strain will no doubt continue to provide novel insight
into the closely related species, F. tularensis. It is essential, how-
ever, to keep the two species separate and utilize standardized
nomenclature for F. novicida. The recognition of F. novicida as
a separate species via consistent and accepted nomenclature will
limit misinterpretation of experimental results as pertains to the
human disease tularemia caused by F. tularensis, avoid confusion
between F. tularensis and F. novicida in clinical settings and ensure
F. tularensis strains are used for treatment efficacy studies.
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